|
ANTIDIURETIC EFFECT IS POTENTIATED BY THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
BEZAFIBRATE POTENTIATES THE ACTION OF THE DRUG
|
DESMOPRESSIN ANTIDIURETIC EFFECT IS REDUCED BY THE DRUG
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
OESTROGENS INCREASE CLEARANCE OF THE DRUG
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS FIBRATES ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS FIBRATES ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS FIBRATES ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS FIBRATES ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
TERLIPRESSIN ANTIDIURETIC EFFECT IS ENHANCED BY THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|
PROGESTERONES ENHANCES PLASMA CLEARANCE OF THE DRUG
|